Company news

Longeveron Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

July 21, 2025

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

July 8, 2025

Longeveron® Appoints Than Powell as Chief Business Officer

June 26, 2025

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

June 24, 2025

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 9, 2025

Longeveron® to Attend BIO International Convention 2025

May 20, 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

April 22, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

March 20, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

March 11, 2025

Longeveron® to Present at the 37th Annual Roth Conference

March 5, 2025

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

February 28, 2025

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

February 21, 2025

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

February 18, 2025

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

December 1, 2024

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

November 10, 2024

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

November 3, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

October 28, 2024

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

October 26, 2024

Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

October 13, 2024

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

October 6, 2024

Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)

September 2, 2024

Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

August 4, 2024

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

July 27, 2024

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

July 17, 2024

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

July 16, 2024

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

July 9, 2024

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

July 7, 2024

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

June 17, 2024

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

June 16, 2024

Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease

June 10, 2024

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

June 2, 2024

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Longeveron Announces Board of Directors Planned Transitions

May 9, 2024

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

May 1, 2024

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

April 17, 2024

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

April 16, 2024

Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)

April 14, 2024

Longeveron Announces Closing of $5.2 Million Public Offering

April 10, 2024

Longeveron Announces Pricing of $5.25 Million Public Offering

April 7, 2024

Longeveron Announces 1-for-10 Reverse Stock Split

March 18, 2024

Longeveron Reports Year-End 2023 Results and Provides Corporate Update

February 26, 2024

Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024

February 20, 2024

Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™

January 28, 2024

Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 20, 2023

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease

December 19, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.